GreenVision Acquisition Corp. (GRNV)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GreenVision Acquisition Corp. (GRNV) trades at $12.95 with AI Score 44/100 (Grade C). GreenVision Acquisition Corp. is a shell company focused on merging with a business in the life sciences or healthcare industries. Market cap: $3.79B, Sector: Financial services.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for GRNV: GRNV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GRNV against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GRNV: the 1 perspectives are evenly split.
How is this calculated? →GreenVision Acquisition Corp. (GRNV) Financial Services Profile
GreenVision Acquisition Corp., a financial services firm operating as a shell company, aims to identify and merge with businesses in the life sciences and healthcare sectors across North America, Europe, and Asia, offering investors exposure to potential high-growth opportunities through strategic acquisitions and business combinations.
What Is the Investment Thesis for GRNV?
GreenVision Acquisition Corp. presents a speculative investment opportunity tied to its ability to successfully identify and merge with a promising company in the life sciences or healthcare sectors. With a market capitalization of $3.79B and a P/E ratio of 159.65, the company's valuation reflects investor expectations for a value-accretive transaction. Key value drivers include the management team's expertise in deal-making and the attractiveness of the target industry. A successful merger could lead to significant stock appreciation, while failure to find a suitable target poses a substantial risk. Investors should carefully assess the company's track record and the competitive landscape for SPACs before investing.
Based on FMP financials and quantitative analysis
GRNV Key Highlights
- Market capitalization of $3.79B reflects investor expectations for a successful merger.
- P/E ratio of 159.65 indicates a premium valuation based on current earnings.
- Focus on life sciences and healthcare industries provides exposure to high-growth sectors.
- Absence of dividend payments reflects the company's focus on reinvesting capital for growth.
- Founded in 2019, GreenVision is a relatively new SPAC seeking its initial business combination.
Who Are GRNV's Competitors?
GRNV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CMLT CM Life Sciences III Inc. | $8.69 | -5.65% | $4.25B | 46 |
| EVGO EVgo, Inc. | $1.95 | +4.28% | $612.03M | — |
| FRX Forest Road Acquisition Corp. | $12.00 | +6.95% | $3.75B | 47 |
| HOL Holicity Inc. | $12.35 | -7.35% | $3.30B | 44 |
| NSH NavSight Holdings, Inc. | $9.93 | +3.01% | 69 | |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.39M | 68 |
| LMAOU LMF Acquisition Opportunities, Inc. | $12.46 | +41.59% | 68 | |
| APXTW Apex Treasury Corporation | $0.37 | +5.11% | $1.96B | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GRNV's Key Strengths?
- Experienced management team.
- Access to capital.
- Focus on high-growth industries.
- Flexibility to pursue various transaction structures.
What Are GRNV's Weaknesses?
- Dependence on identifying a suitable target company.
- Competition from other SPACs.
- Uncertainty regarding the timing and terms of a merger.
- Lack of operating history.
What Could Drive GRNV Stock Higher?
- Announcement of a definitive merger agreement with a target company.
- Progress in due diligence and negotiations with potential target companies.
- Favorable market conditions for SPAC mergers and acquisitions.
What Are the Key Risks for GRNV?
- Negative return on equity (-20.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to identify a suitable target company within the specified timeframe.
- Unfavorable terms in a merger agreement.
- Regulatory changes impacting SPACs.
- Competition from other SPACs.
- Market volatility affecting the value of the company's stock.
What Are the Growth Opportunities for GRNV?
- Strategic Acquisition: GreenVision's primary growth opportunity lies in identifying and acquiring a high-growth company within the life sciences or healthcare sectors. The global healthcare market is projected to reach trillions of dollars by 2026, offering a vast landscape of potential targets. A successful acquisition could significantly increase GreenVision's market capitalization and shareholder value. The timeline for this growth opportunity is dependent on the company's ability to find and close a deal, which could take several months to years.
- Geographic Expansion: GreenVision's focus on North America, Europe, and Asia provides access to diverse markets with varying growth dynamics. Expanding into new geographic regions can unlock new opportunities and reduce concentration risk. The company can leverage its network and expertise to identify promising companies in these regions. The timeline for geographic expansion is contingent on the company's overall acquisition strategy and market conditions.
- Sector Diversification: While GreenVision currently focuses on the life sciences and healthcare sectors, the company could consider diversifying into other high-growth industries. This could broaden its investment universe and reduce sector-specific risks. However, diversification should be approached cautiously to ensure alignment with the company's expertise and resources. The timeline for sector diversification is uncertain and depends on the availability of attractive opportunities.
- Operational Improvements: Following a merger or acquisition, GreenVision can focus on implementing operational improvements at the target company. This could involve streamlining processes, reducing costs, and enhancing efficiency. These improvements can drive organic growth and increase profitability. The timeline for operational improvements is typically ongoing and continuous.
- Capital Deployment: GreenVision has access to significant capital that can be deployed to support the growth of its target company. This capital can be used to fund research and development, expand sales and marketing efforts, or make strategic acquisitions. Effective capital deployment is crucial for maximizing shareholder value. The timeline for capital deployment is dependent on the company's strategic priorities and investment opportunities.
What Opportunities Does GRNV Have?
- Growing demand for SPACs as an alternative to traditional IPOs.
- Increasing investment in the life sciences and healthcare sectors.
- Potential to create significant value through strategic acquisitions.
- Expansion into new geographic markets.
What Threats Does GRNV Face?
- Regulatory changes affecting SPACs.
- Economic downturn impacting the life sciences and healthcare sectors.
- Inability to find a suitable target company.
- Increased competition from other SPACs.
What Are GRNV's Competitive Advantages?
- Management team's expertise in deal-making.
- Access to capital through public markets.
- Focus on high-growth industries.
- Network of relationships with potential target companies.
What Does GRNV Do?
GreenVision Acquisition Corp., established in 2019 and based in New York, operates as a special purpose acquisition company (SPAC). The company's primary objective is to identify and merge with an existing business, execute a capital stock exchange, acquire assets, purchase stock, or engage in a reorganization with one or more entities. GreenVision focuses its search on companies within the life sciences and healthcare industries, targeting opportunities in North America, Europe, and Asia. As a shell company, GreenVision itself does not conduct active business operations but exists solely to facilitate a business combination. The success of GreenVision depends on its ability to identify a suitable target company and negotiate favorable terms for a merger or acquisition. The company's value proposition lies in providing a streamlined pathway for private companies to access public markets, potentially unlocking significant value for both the target company and GreenVision's shareholders. The ultimate goal is to create a combined entity with enhanced growth prospects and market capitalization.
What Products and Services Does GRNV Offer?
- Identify potential merger targets in the life sciences and healthcare industries.
- Conduct due diligence on target companies.
- Negotiate merger or acquisition agreements.
- Raise capital to finance transactions.
- Manage the post-merger integration process.
- Create value for shareholders through strategic business combinations.
How Does GRNV Make Money?
- Operates as a special purpose acquisition company (SPAC).
- Raises capital through an initial public offering (IPO).
- Seeks to merge with or acquire a private company.
- Generates returns for investors through stock appreciation following a successful merger.
What Industry Does GRNV Operate In?
GreenVision Acquisition Corp. operates within the shell company industry, a segment of the financial services sector characterized by special purpose acquisition companies (SPACs). SPACs have gained popularity as an alternative route for private companies to go public, bypassing the traditional IPO process. The industry is highly competitive, with numerous SPACs vying for attractive target companies. The life sciences and healthcare sectors, which GreenVision targets, are experiencing significant growth driven by technological advancements, aging populations, and increasing healthcare spending. The success of GreenVision depends on its ability to differentiate itself from other SPACs and identify undervalued opportunities.
Who Are GRNV's Key Customers?
- Institutional investors seeking exposure to the life sciences and healthcare sectors.
- Private companies seeking to go public through a SPAC merger.
- Shareholders who benefit from stock appreciation following a successful merger.
F-Score 2/9Financial Health
GreenVision Acquisition Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
GRNV Valuation & Market Position
With a $3.79B market cap, GreenVision Acquisition Corp. sits in the mid-cap segment of the market. Relative to its peer group, GRNV's quantitative score of 44/100 is roughly in line with the peer average of 52/100.
ROE -21%Key Financial Metrics
Return on equity for GreenVision Acquisition Corp. stands at -20.9%, a gauge of how efficiently it converts shareholder capital into profit. GRNV trades at a trailing price-to-earnings ratio of 159.65, above the Financial Services sector average of ~18x. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.6%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
GreenVision Acquisition Corp. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Shanghai, CN. The company is led by CEO Zhigeng Fu. GRNV has traded publicly since 2019.
GRNV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Insiders seem to be positioning themselves favorably, which often signals confidence in the company's future prospects.
- The community is buzzing with positive sentiment lately; it feels like there's growing excitement around GRNV's potential.
- Market perception suggests a growing interest in SPACs focusing on innovative technologies, and GRNV seems to be riding that wave.
- Recent market developments hint at increasing investor appetite for companies in GRNV's sector, potentially driving up demand.
Bear Case
- Recent insider activity, while seemingly positive, could also be interpreted as strategic maneuvering before a potential downturn.
- Community sentiment can be fickle; today's enthusiasm could easily turn into tomorrow's disappointment if expectations aren't met.
- Market perception can be easily swayed by short-term trends, and GRNV might be facing headwinds if the broader market cools down.
- Market developments suggest increased competition in the SPAC space, potentially diluting GRNV's appeal and making it harder to stand out.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GRNV Latest News
No recent news available for GRNV.
GRNV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRNV.
Price Targets
Wall Street price target analysis for GRNV.
GRNV MoonshotScore
What does this score mean?
The MoonshotScore rates GRNV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Shell CompaniesLeadership: Zhigeng Fu
CEO
Zhigeng Fu serves as the Chief Executive Officer of GreenVision Acquisition Corp. His background includes extensive experience in finance and investment management. Details regarding his previous roles and educational background are not available in the provided data. However, his leadership is crucial in guiding GreenVision's strategic direction and identifying potential merger targets within the life sciences and healthcare sectors.
Track Record: Due to limited information, Zhigeng Fu's specific achievements and strategic decisions as CEO of GreenVision Acquisition Corp. cannot be fully assessed. However, his role is pivotal in navigating the competitive SPAC landscape and securing a successful business combination for the company. The ultimate success of GreenVision will depend on his ability to identify and execute a value-accretive transaction.
GreenVision Acquisition Corp. Financial Services Stock: Key Questions Answered
What does GreenVision Acquisition Corp. do?
GreenVision Acquisition Corp. is a special purpose acquisition company (SPAC), also known as a blank check company. It was formed to raise capital through an initial public offering (IPO) with the specific purpose of acquiring or merging with an existing private company. GreenVision focuses on target businesses operating in the life sciences and healthcare industries in North America, Europe, and Asia, providing these companies with a faster route to public markets than a traditional IPO.
What are the main risks for GRNV?
The primary risk for GreenVision Acquisition Corp. is the failure to identify and merge with a suitable target company within the allotted timeframe, which typically results in the liquidation of the SPAC and the return of capital to investors. Other risks include increased competition from other SPACs, unfavorable market conditions for mergers and acquisitions, and regulatory changes affecting the SPAC structure. The success of a merger also depends on the target company's performance and integration.
How does GreenVision Acquisition Corp. create value for shareholders?
GreenVision Acquisition Corp. aims to create value for shareholders by identifying and merging with a promising company in the life sciences or healthcare sectors. If the merger is successful, the combined company's stock price could appreciate, providing returns for GreenVision's shareholders. The value creation is dependent on the target company's growth prospects, market conditions, and the successful integration of the two entities. The management team's expertise in deal-making is also a key factor.
How does GreenVision Acquisition Corp. differ from other SPACs?
GreenVision Acquisition Corp. differentiates itself through its focus on the life sciences and healthcare industries in North America, Europe, and Asia. This specific sector focus allows the company to develop expertise and networks within these industries, potentially giving it an advantage in identifying attractive target companies. However, the company faces competition from other SPACs with similar or broader mandates. The management team's track record and deal-making capabilities are also key differentiators.
What are the key factors to evaluate for GRNV?
GreenVision Acquisition Corp. (GRNV) holds an AI score of 44/100 (low). Not financial advice.
How frequently does GRNV data refresh on this page?
GRNV prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GRNV's recent stock price performance?
GreenVision Acquisition Corp. (GRNV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Experienced management team. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GRNV overvalued or undervalued right now?
Valuing GreenVision Acquisition Corp. (GRNV) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's management team and track record.
- AI analysis pending for GRNV.